AWAREness of diagnosis and treatment of Chronic Kidney Disease in adults with Type 2 Diabetes (AWARE-CKD in T2D)
Diabetes remains the leading contributor to the development of chronic kidney disease (CKD) and end stage kidney disease, emphasizing the urgency of identifying barriers to early diagnosis and intervention. The AWARE-CKD in T2D study described the awareness, values, and preferences of physicians (general practitioners, endocrinologists, and nephrologists) and patients on the management of chronic kidney disease in patients with type 2 diabetes (CKD in T2D). The results of the survey study highlighted opportunities for improving CKD in T2D management, such as earlier referrals to nephrologists and additional education and clarity for physicians on urinary albumin testing for assessing kidney risk. More understanding of kidney risk progression is also vital for patients.
Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database
Randomized comparison of initiating the fixed-ratio combination of iGlarLixi or biosimilar insulin glargine together with gliclazide in South Asian origin participants with Type 2 Diabetes: VARIATION 2 SA trial
Individuals of South Asian (SA) origin comprise nearly 2 billion people worldwide, and form the largest ethnic minority population in Canada. Higher prevalence of type 2 diabetes (T2D) among immigrants of SA origin is well documented compared to other ethnicities in Canada. Hence, therapy recommendations have included utilizing combination treatment approaches and incorporating insulin earlier in disease progression. A fixed-ratio combination (FRC) of a daily basal insulin/GLP-1 RA might be ideal for this population given the relatively high daytime carbohydrate consumption, relatively lower insulin requirements, and a cultural dislike of multiple therapies.
The VARIATION 2 SA trial compared the initiation of a FRC of insulin glargine and lixisenatide (iGlarLixi) vs insulin glargine U100 (iGlar) along with gliclazide, exclusively in people of SA origin with T2D. The initiation of iGlarLixi resulted in similar time-in-range, HbA1c, fasting plasma glucose, weight and hypoglycemia compared to the more affordable option of starting iGlar + gliclazide in SA origin adults with T2D.
Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database